Submitted by web@researchtop... on Mon, 08/02/2010 - 12:31
Use of Bevacizumab in the Maintenance Setting for Patients with Metastatic Colorectal Cancer (mCRC)
| CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
| Read Dr Love's original email (from August 3, 2010) | Subscribe to Dr Love's email alerts | ||
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Richard M Goldberg, MD (6/23/10), Axel Grothey, MD (7/9/10) and Alan P Venook, MD (6/16/10)
Tabernero J et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent BEV as maintenance therapy in patients with metastatic colorectal cancer: The MACRO trial. Proc ASCO 2010;Abstract 3501.